LAVA Therapeutics N.V. is a limited liability public company (naamloze vennootschap) under the laws of the Netherlands with its registered office at Yalelaan 62, 3584 CM Utrecht, the Netherlands, and its phone number is +31 85 016 3100. In 2019, we established our wholly-owned U.S. subsidiary, LAVA Therapeutics, Inc., which began business in January 2020. We completed an initial public offering in the United States in March 2021, and our common shares began trading on the Nasdaq Global Select Market on March 25, 2021. In connection with becoming a public company, on March 29, 2021, the Company changed its name from “LAVA Therapeutics, B.V.” to “LAVA Therapeutics N.V.”
Company profile
Ticker
LVTX
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
LAVA Therapeutics BV
SEC CIK
LVTX stock data
Latest filings (excl ownership)
6-K
Current report (foreign)
21 Mar 24
20-F
2023 FY
Annual report (foreign)
20 Mar 24
6-K
Current report (foreign)
16 Nov 23
6-K
Current report (foreign)
22 Aug 23
6-K
Current report (foreign)
15 Aug 23
6-K
Lava Therapeutics Provides Updates on Clinical Programs and Extends the Cash Runway
15 Jun 23
6-K
Current report (foreign)
8 Jun 23
6-K
Gamma delta T cell engagers for the development of next-generation cancer therapeutics Corporate Presentation April 2023
24 Apr 23
6-K
Lava Therapeutics Provides Business Update and Reports Fourth Quarter and Year-end 2022 Financial Results
12 Apr 23
20-F
2022 FY
Annual report (foreign)
11 Apr 23
Latest ownership filings
SC 13D/A
Novo Holdings A/S
7 Mar 24
SC 13G/A
Redmile Group, LLC
14 Feb 24
SC 13D/A
Novo Holdings A/S
9 Nov 23
SC 13D/A
Novo Holdings A/S
6 Jun 23
144
Notice of proposed sale of securities
5 Jun 23
SC 13D/A
Novo Holdings A/S
24 Feb 23
SC 13D/A
Novo Holdings A/S
3 Oct 22
SC 13D/A
Novo Holdings A/S
30 Sep 22
SC 13G/A
Redmile Group, LLC
14 Feb 22
SC 13D
Versant Venture Capital VI, L.P.
8 Apr 21
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Institutional ownership, Q2 2023
62.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 19 |
Opened positions | 11 |
Closed positions | 3 |
Increased positions | 1 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 11.37 bn |
Total shares | 16.49 mm |
Total puts | 0.00 |
Total calls | 17.10 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Cooperatieve Gilde Healthcare IV U.A. | 5.42 mm | $67.77 mm |
Versant Venture Capital VI | 3.41 mm | $43.27 mm |
Novo Holdings A/S | 2.40 mm | $4.87 bn |
Redmile | 2.07 mm | $4.21 bn |
SNY Sanofi | 1.92 mm | $27.45 mm |
Bruce & Co. | 771.87 k | $1.57 bn |
Artal | 200.00 k | $406.00 k |
Falcon Edge Capital | 109.10 k | $221.47 mm |
Millennium Management | 80.37 k | $163.16 mm |
PNC PNC Financial Services | 65.00 k | $131.95 mm |
News
HC Wainwright & Co. Reiterates Buy on LAVA Therapeutics, Maintains $6 Price Target
21 Mar 24
LAVA Therapeutics Q4 EPS $(0.24) Misses $(0.12) Estimate, Sales $353.00K Miss $6.25M Estimate
20 Mar 24
LAVA Therapeutics N.V Filed U.S. Patent Application #20240067726-A1 For "Single Domain Antibodies Targeting CD1D"
29 Feb 24
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet (Donald Trump Has Re-Entered The Chat)
26 Jan 24
Why Humana Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
25 Jan 24
Press releases
Thinking about buying stock in Beyondspring, LAVA Therapeutics, Unicycive Therapeutics, Guardforce AI, or Infobird?
6 Mar 24
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
5 Mar 24
LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)
5 Mar 24
Thinking about buying stock in Societal CDMO, LAVA Therapeutics, Eastman Kodak, Brightspring Health Services, or Codexis?
1 Mar 24
Nasdaq Stocks Above $2 to Watch Now! LVTX, INBS, IKT, PCSA, DYAI
29 Jan 24